Paul Matteis
Stock Analyst at Stifel
(1.39)
# 3,404
Out of 4,884 analysts
113
Total ratings
39.73%
Success rate
-11.86%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $65.77 | +42.92% | 2 | May 29, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Hold | $11 → $8 | $7.99 | +0.13% | 2 | May 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $331.91 | +3.94% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $0.82 | +143.43% | 2 | Mar 7, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $21.19 | +51.01% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $14.92 | +114.55% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $3.26 | +237.42% | 1 | Feb 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $459.62 | +7.48% | 18 | Dec 16, 2024 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $14.42 | +121.91% | 1 | Dec 16, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $6 | $9.20 | -34.78% | 5 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.51 | +164.90% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.35 | +325.53% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $20.09 | +198.66% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $28.85 | +24.78% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $57.50 | +51.30% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $66 | $8.76 | +653.42% | 3 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $12.04 | +190.70% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $43.00 | +23.26% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $20.95 | +0.24% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $3.88 | +647.42% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $129.11 | +11.53% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $132.87 | +116.00% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.45 | +349.44% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.00 | +500.00% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.22 | +1,867.21% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.34 | +1,370.59% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $11.98 | +167.11% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.16 | +2,227.59% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $8.93 | +56.77% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $6.95 | +820.86% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $48.78 | +597.01% | 1 | Dec 21, 2016 | |
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $65.77
Upside: +42.92%
Vigil Neuroscience
May 28, 2025
Downgrades: Hold
Price Target: $11 → $8
Current: $7.99
Upside: +0.13%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $331.91
Upside: +3.94%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $0.82
Upside: +143.43%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $21.19
Upside: +51.01%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $14.92
Upside: +114.55%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $3.26
Upside: +237.42%
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $459.62
Upside: +7.48%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $14.42
Upside: +121.91%
Sage Therapeutics
Dec 16, 2024
Maintains: Hold
Price Target: $10 → $6
Current: $9.20
Upside: -34.78%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.51
Upside: +164.90%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.35
Upside: +325.53%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $20.09
Upside: +198.66%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $28.85
Upside: +24.78%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $57.50
Upside: +51.30%
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $8.76
Upside: +653.42%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $12.04
Upside: +190.70%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $43.00
Upside: +23.26%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $20.95
Upside: +0.24%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $3.88
Upside: +647.42%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $129.11
Upside: +11.53%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $132.87
Upside: +116.00%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $4.45
Upside: +349.44%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.00
Upside: +500.00%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.22
Upside: +1,867.21%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.34
Upside: +1,370.59%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $11.98
Upside: +167.11%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.16
Upside: +2,227.59%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $8.93
Upside: +56.77%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $6.95
Upside: +820.86%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $48.78
Upside: +597.01%